Effectiveness of Paliperidone ER(Invega®) on Depressive Symptoms of Schizophrenia Patients: A 8-week Open-label Prospective, Non-comparative Study.
Phase of Trial: Phase IV
Latest Information Update: 04 Dec 2017
At a glance
- Drugs Paliperidone (Primary)
- Indications Schizophrenia
- Focus Therapeutic Use
- 07 Dec 2015 Planned End Date changed from 1 Jul 2014 to 1 Jul 2016 as reported by ClinicalTrials.gov.
- 07 Dec 2015 Planned primary completion date changed from 1 Mar 2014 to 1 Jul 2016 as reported by ClinicalTrials.gov.
- 10 May 2012 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.